Year 7, Number 27, January 2005

 

Oncology

 

 


Coelho-Oliveira, Afrânio[1]; Gutfilen, Bianca[1]: Ricardo Chagas, Carlos[1,2]; Lopes de Souza, Sérgio Augusto[1]; Pinheiro Pessoa, Maria Carolina[1]; Barbosa da Fonseca, Lea Mirian[1].

[1] Departamento de Radiologia, Serviço de Medicina Nuclear, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
[2]Serviço de Ginecologia
[2]Santa Casa de Misericórdia do Rio de Janeiro.

Correspondencia:

Sergio A. Lopes de Souza
E-mail: sergioalsouza@ufrj.br
Fono:21-22443351

Lea M. Barbosa da Fonseca
E-mail: leamirian@globo.com
Fono: (21) 2537-1089

Cita/Reference:
Coelho-Oliveira, Afrânio; Gutfilen, Bianca; Ricardo Chagas, Carlos. et al. Identification of Sentinel Node in Breast Cancer: Injection of the radiopharmaceutical in four points. Alasbimn Journal 7(27): January 2005



Identification of Sentinel Node in Breast Cancer: Injection of the radiopharmaceutical in four points


Axillary node status is the most important prognostic factor for patients with primary breast carcinoma. The sentinel node biopsy (SN) technique has received much attention as a possible alternative to axillary lymph node dissection.

The aim of this study is to identify the sentinel node by periareolar and subdermal injection of the radiopharmaceutical in four points, independent of tumor topography and the presence of biopsies and/or previous surgery.

The peritumoral injection technique was carried out for comparison purpose. This study was performed in 115 patients, divided in 2 groups: Group A (25 patients, peritumoral injection) and Group B (90 patients, injection in four points). All the SN biopsies were studied by touch preparation cytology and H&E staining. Control axillary lymph-node dissection was followed in all patients from Group A and in those positive cases from Group B. Twenty-two of the twenty-five (88%) SN were identified in Group A. There was no false negative; the sensitivity and specificity were 100%. Eighty-two of the ninety (91.1%) SN were identified in Group B. Lymphoscintigraphy showed radiopharmaceutical migration to axilla in 93.7% of the cases. Hotspot area was 10 to 100 times the background radiation. Among the 92 cases with negative sentinel nodes at intraoperative examination (TP), the SN histopathology confirmed the absence of cancer cells in 89, whereas in 3 patients with SNs were negative in TP were positive in IHC for metastatic cells.

This study shows that periareolar injection in four points seems to be a good lymphatic mapping method for SN identification. We suggest standardizing this site of injection to identify the SN. More studies to confirm these findings are ongoing.

 


Correlation Between PSA Level, Gleason Score and Bone Scan in Staging of Prostate Cancer Patients | Lymphatic Mapping and Sentinel Node Detection using 99mTc-Phytate in Cervix Cancer - 55 cases | Use of 99mTc-Phytate for Lymphoscintigraphy and Sentinel Node Biopsy in 858 Patients with Breast Cancer | Whole-Body Tc-99m Sestamibi Scintigraphy in the Pre-Operative Evaluation of differentiated Thyroid Carcinoma | Lymphatic Mapping and Detection of Sentinel Lymph Node in Vulvar Cancer | Calculation of a 99mTc sestamibi concentration index in suspect breast lesions. Where should the area of interest necessary to establish a reference value be? | Scintimammography with 99mTc sestamibi of suspect nodules - Quantitative analysis | Efficiency of scintimammography with 99mTc sestamibi in the detection of cancer | Identification of Sentinel Node in Breast Cancer: Injection of the radiopharmaceutical in four points | The influence of histological grading in the detection of breast carcinoma on scintimammography | Determinant factors of thyroid function outcome in patients with graves' Disease after radioiodine therapy | Parathyroid Scintigraphy with 99mTc-Sestamibi: The Value of Sequential Images to Plan Minimally Invasive Radioguided Parathyroidectomy | 99mTc -Sestamibi in differential diagnosis of congenital hypothyroidism in children under hormone therapy | Print

 

 

Sitio desarrollado por SISIB - Universidad de Chile